Currentmedical mutual - ohioPolicy N/A

Jakafi (ruxolitinib) — Coverage Criteria

Defines prior authorization, coverage criteria, approval durations, and conditions not recommended for approval for Jakafi (ruxolitinib) for Medical Mutual - Ohio pharmacy benefit; applies to prescribers and patients seeking coverage.

Policy Summary

Payermedical mutual - ohio

PolicyJakafi (ruxolitinib) — Coverage Criteria

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateN/A

Next Review DateOct 16, 2026

Key ActionObtain prior authorization with prescription by or in consultation with a hematologist or oncologist.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 yrInitial approval duration

1 yrExtended approval duration

18+Min age (MF/PV)

12+Min age (GVHD)

AlopeciaNot recommended

Recommended Authorization & Exclusions

Recommended Authorization Criteria

Covered when ALL of the following are met for each listed indication

Myelofibrosis (MF): Patient has MF (primary, post-polycythemia vera, or post-essential thrombocytopenia) AND is >= 18 years of ageage >= 18

Approve if both conditions are met

Polycythemia Vera: Patient is >= 18 years of age AND has had an inadequate response or intolerance to hydroxyureaage >= 18; prior hydroxyurea trial or intolerance

Approve when both conditions are met

Graft Versus Host Disease (GVHD): Patient is >= 12 years of age AND (has steroid-refractory acute GVHD OR has chronic GVHD and has failed at least one line of systemic therapy)

Policy Summary

Payermedical mutual - ohio

PolicyJakafi (ruxolitinib) — Coverage Criteria

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateN/A

Next Review DateOct 16, 2026

Key ActionObtain prior authorization with prescription by or in consultation with a hematologist or oncologist.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Prior Authorization, Documentation, and Denial Conditions

Prior Authorization

Prior Authorization and Prescriber Requirement

Prior authorization is recommended for pharmacy benefit coverage of Jakafi. Initial approval requires the drug be prescribed by or in consultation with a physician who specializes in the condition being treated (hematologist or oncologist).

Prior authorization recommended for pharmacy benefit coverage
Initial prescription must be by or in consultation with a hematologist or oncologist

Step Therapy

Hydroxyurea Trial Requirement for Polycythemia Vera

For polycythemia vera, approval is recommended only when the patient is 18 years of age or older and has had an inadequate response to or intolerance of hydroxyurea prior to receiving Jakafi.

Polycythemia vera: patient ≥ 18 years
Must have inadequate response or intolerance to hydroxyurea prior to approval

Documentation Required

Documentation to Support Medical Necessity

The Company may request supporting medical documentation to verify medical necessity. Documentation that may be requested includes patient medical records, relevant test results, treatment history (including prior therapies and responses), and credentials of the provider ordering or performing the service. Providers must make documentation available upon request as part of the coverage determination process.

Possible requested documentation: patient records, lab/test results, prior treatment history, provider credentials
Documentation must be provided upon request to support medical necessity

Denial Risk

Denial Conditions and Triggers

The Company may deny reimbursement when the drug or services were not medically necessary, were investigational or experimental, were not within the member's benefit scope, or when inappropriate or excessive billing or practice patterns are identified.

Denial triggers include: not medically necessary, investigational/experimental, outside scope of benefits, inappropriate/excessive billing patterns

OpenPayer

Jakafi (ruxolitinib) — Coverage Criteria

Recommended Authorization & Exclusions

Prior Authorization, Documentation, and Denial Conditions

Key Condition Definitions

Drug Background